Vesatolimod

DRUG6 trials

Sponsors

Gilead Sciences

Conditions

Chronic Hepatitis BHIV-1 InfectionHIV-1-infectionHuman Immunodeficiency Virus Type 1 (HIV-1) Infection

Phase 1

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

CompletedNCT02858401

Gilead SciencesHIV-1 Infection

Start: 2015-01-29End: 2019-02-14Updated: 2020-02-21

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers

CompletedNCT03060447

Gilead SciencesHIV-1 Infection

Start: 2017-05-09End: 2020-02-13Updated: 2021-04-21

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

TerminatedNCT05458102

Gilead SciencesHuman Immunodeficiency Virus Type 1 (HIV-1) Infection

Start: 2022-08-19End: 2023-05-01Updated: 2024-12-03

Phase 2

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

CompletedNCT02166047

Gilead SciencesChronic Hepatitis B

Start: 2014-06-30End: 2016-10-20Updated: 2020-10-14

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

CompletedNCT02579382

Gilead SciencesChronic Hepatitis B

Start: 2015-11-10End: 2019-05-03Updated: 2020-05-18

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

CompletedNCT05281510

Gilead SciencesHIV-1-infection

Start: 2022-06-09End: 2025-01-16Updated: 2026-01-16

Related Papers

Rational Design and Identification of Highly Selective TLR8 Agonists as Potent HIV-1 Latency Reversal Agents.

2026-02-25

Psychological Impact of Analytical Treatment Interruption on Young Women Enrolled in an HIV Cure-Related Clinical Trial in Durban, South Africa.

2025-12-22

The Effects of Cobicistat and Voriconazole on the Safety, Pharmacokinetics, and Pharmacodynamics of the TLR7 Agonist Vesatolimod in People with HIV.

2025-09-15

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

Nature Communications2025-03-0416 citations

Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection

JCI Insight2025-02-235 citations

HIV rebound in HIV controllers is associated with a specific fecal microbiome profile

European Journal of Immunology2024-05-101 citations

Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus–1

Clinical Infectious Diseases2020-10-0672 citations

From the Editor’s desk...

Journal of Hepatology2015-05-15